Lv5
996 积分 2024-11-20 加入
First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study
2天前
已完结
Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial
16天前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
30天前
已完结
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
30天前
已完结
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma
30天前
已完结
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
1个月前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
1个月前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
2个月前
已完结
Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study
2个月前
已完结
皖公网安备34019202002308
